Monoclonal antibody aiming at papilloma virus type 18 E protein
By designing specific monoclonal antibodies to bind papillomavirus type 18 E protein, the insufficient treatment of HPV-18 E protein in the prior art has been solved, and high affinity and stability have been achieved. It is suitable for the treatment of HPV-18-related cancers. and diagnosis.
Patent Information
- Application Number
- CN202411279668.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-12
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-12
AI Technical Summary
The prior art is difficult to effectively target papillomavirus type 18 E protein, especially in the development of high-affinity monoclonal antibodies, which affects the treatment and diagnosis of HPV-18-related cancers.
A monoclonal antibody was designed to specifically bind papillomavirus type 18 E protein, including heavy and light chain variable regions, encoded by specific amino acid sequences and polynucleotides, binding to buffers, stabilizers and nonionic Surfactant, forming suitable compositions to improve the affinity and stability of the antibody.
It has achieved efficient binding to papillomavirus type 18 E protein, and provided a high-affinity monoclonal antibody, suitable for the treatment and diagnosis, especially HPV-18-related cancers, significantly improving the therapeutic and monitoring effect.
Smart Images

Figure CN119019545A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology and relates to a monoclonal antibody against papillomavirus type 18 E protein. Background Art
[0002] Papillomavirus (English: Humanpapillomavirus, abbreviated: HPV) is a non-enveloped DNA virus belonging to the genus Papillomavirus of the family Papillomaviridae. This type of virus infects the epidermis and mucous membranes of the human body. Sometimes HPV can cause warts or even cancer after invading the human body, but most of the time there are no clinical symptoms. Human papillomavirus can be divided into 5 genera based on the differences in their L1 gene DNA sequences. As of September 2023, 231 types of HPV have been identified.
[0003] There are about 30 to 40 types of HPV that can infect the genitals and surrounding skin through sexual intercourse, and some of them can cause genital warts (commonly known as cauliflower). If you are repeatedly infected with certain high-risk HPV types without symptoms such as warts, you may develop precancerous lesions or even invasive cancer. According to research, 99.7% of cervical cancer is caused by infection with HPV. According to data from the International Agency for Research on Cancer, 70% of cervical cancer cases are caused by two high-risk types, HPV-16 and HPV-18.
[0004] HPV infection of the reproductive tract is a long-term process. It can remain latent in cells for several years. Once the opportunity is ripe (such as when the host's immunity is reduced), the latent virus can resume activity. The HPV infection process is usually divided into the latent infection period, subclinical infection period, clinical symptom period and HPV-related tumor period. Cervical cancer also has a series of precursor lesions, namely atypical hyperplasia of the cervical epithelium, which is pathologically called cervical intraepithelial neoplasia (CIN). It is usually divided into three levels according to the severity: mild cervical intraepithelial neoplasia (CIN I), moderate cervical intraepithelial neoplasia (CIN II) and high cervical intraepithelial neoplasia (CIN III). These precancerous lesions may develop into invasive cervical cancer. Summary of the invention
[0005] In order to solve the technical problems existing in the prior art, the present invention provides the following technical solutions:
[0006] In a first aspect, the present invention provides a monoclonal antibody, which specifically binds to papillomavirus type 18 E protein, and the monoclonal antibody comprises a heavy chain variable region, including a heavy chain CDR1 with an amino acid sequence as shown in SEQ ID NO:1, a heavy chain CDR2 with an amino acid sequence as shown in SEQ ID NO:2, and a heavy chain CDR3 with an amino acid sequence as shown in SEQ ID NO:3; and a light chain variable region, including a light chain CDR1 with an amino acid sequence as shown in SEQ ID NO:9, a light chain CDR2 with an amino acid sequence as shown in YTS, and a light chain CDR3 with an amino acid sequence as shown in SEQ ID NO:10.
[0007] Further, the heavy chain variable region includes a heavy chain variable region framework region, which includes a heavy chain FR1 of the amino acid sequence shown in SEQ ID NO:4 or a homologous sequence thereof, a heavy chain FR2 of the amino acid sequence shown in SEQ ID NO:5 or a homologous sequence thereof, a heavy chain FR3 of the amino acid sequence shown in SEQ ID NO:6 or a homologous sequence thereof, and a heavy chain FR4 of the amino acid sequence shown in SEQ ID NO:7 or a homologous sequence thereof; the light chain variable region includes a light chain variable region framework region, which includes a light chain FR1 of the amino acid sequence shown in SEQ ID NO:11 or a homologous sequence thereof, a light chain FR2 of the amino acid sequence shown in SEQ ID NO:12 or a homologous sequence thereof, a light chain FR3 of the amino acid sequence shown in SEQ ID NO:13 or a homologous sequence thereof, and a light chain FR4 of the amino acid sequence shown in SEQ ID NO:14 or a homologous sequence thereof.
[0008] Furthermore, the monoclonal antibody comprises a heavy chain variable region amino acid sequence of the sequence shown in SEQ ID NO: 8 or a homologous sequence thereof and a light chain variable region amino acid sequence of the sequence shown in SEQ ID NO: 15 or a homologous sequence thereof.
[0009] Furthermore, the homology between the homologous sequence and the original sequence is greater than 60%.
[0010] Furthermore, the homology between the homologous sequence and the original sequence is greater than 90%.
[0011] Exemplarily, the homology of the homologous sequence to the original sequence is 60% or more, for example, about 60% or more, about 70% or more, 71% or more, 72% or more, 73% or more, 74% or more, 75% or more, 76% or more, 77% or more, 78% or more, 79% or more, 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more, etc.
[0012] Illustratively, the heavy chain is linked to the light chain directly or via a linker peptide.
[0013] In some embodiments, the anti-CD33 antibody or antigen-binding fragment thereof targeting papillomavirus type 18 E protein comprises a heavy chain and a light chain.
[0014] For some uses, it is desirable to obtain an anti-E protein monoclonal antibody with a high affinity for E protein. For certain uses, such as therapeutic uses, it is desirable to obtain an affinity of at least about 100 nM, although antibodies with higher affinities may be desired, such as at least about 90 nM, 80 nM, 70 nM, 60 nM, 50 nM, 40 nM, 30 nM, 25 nM, 20 nM, 15 nM, 10 nM, 7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.1 nM, 0.01 nM or even higher affinities. Specific exemplary anti-E protein monoclonal antibodies disclosed herein show an affinity of from 10 -6 Up to 10 -12 Affinity within the range of 1:100 M. Anti-E protein monoclonal antibodies with affinities particularly suitable for a desired specific application can be easily selected from these, or produced or designed using a variety of immunogens, complementary determining region (CDR) sequences, variable heavy chain VH and variable light chain VL sequences and methods described herein. The affinity of any specific anti-E protein monoclonal antibody can be determined using techniques known in the art or described herein, such as ELISA, isothermal titration calorimetry (ITC), BIAcore or fluorescence polarization assays.
[0015] Anti-E protein monoclonal antibodies may be of human or non-human origin. Examples of non-human anti-E protein monoclonal antibodies include, but are not limited to, those of mammalian origin (e.g., monkeys, rodents, goats, and rabbits). Humanized anti-E protein monoclonal antibodies for therapeutic use in humans are preferred.
[0016] The "E protein" used in the present invention is the same as the "papillomavirus type 18 E protein", which refers to the E protein possessed by HPV-18 in HPV. It not only exists in HPV-18, but also exists in papillomaviruses (including HPV-1, HPV-5, HPV-8, HPV-14, HPV-20, HPV-21, HPV-25, HPV-47, HPV-6, HPV-11, HPV-16, HPV-18, HPV-31, HPV-33, HPV-35, HPV-39, HPV-41, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-70, and HPV-72). Therefore, in a broad sense, the "E protein" used in the present invention refers to the E protein in the HPV virus.
[0017] The second aspect of the present invention provides a composition comprising the monoclonal antibody according to the first aspect of the present invention and a buffer, a stabilizer, a preservative, a non-ionic detergent, and / or an antioxidant.
[0018] Buffers help maintain pH within a range close to physiological conditions. They can be present at a concentration in the range of about 2 mM to about 50 mM. Buffers suitable for use in the present disclosure include both organic and inorganic acids and their salts, such as citric acid buffers (e.g., monosodium citrate-disodium citrate mixtures, citric acid-trisodium citrate mixtures, citric acid-monosodium citrate mixtures, etc.), succinic acid buffers (e.g., succinic acid-monosodium succinate mixtures, succinic acid-sodium hydroxide mixtures, succinic acid-disodium succinate mixtures, etc.), tartaric acid buffers (e.g., tartaric acid-sodium tartrate mixtures, tartaric acid-potassium tartrate mixtures, tartaric acid-sodium hydroxide mixtures, etc.), fumaric acid buffers (e.g., fumaric acid-monosodium fumarate mixtures, In some embodiments, the present invention can be used as a buffer (e.g., a mixture of fumaric acid and disodium fumarate, a mixture of monosodium fumarate and disodium fumarate, etc.), a gluconic acid buffer (e.g., a mixture of gluconic acid and sodium gluconate, a mixture of gluconic acid and sodium hydroxide, a mixture of gluconic acid and potassium gluconate, etc.), an oxalic acid buffer (e.g., a mixture of oxalic acid and sodium oxalate, a mixture of oxalic acid and sodium hydroxide, a mixture of oxalic acid and potassium oxalate, etc.), a lactic acid buffer (e.g., a mixture of lactic acid and sodium lactate, a mixture of lactic acid and sodium hydroxide, a mixture of lactic acid and potassium lactate, etc.), and an acetic acid buffer (e.g., a mixture of acetic acid and sodium acetate, a mixture of acetic acid and sodium hydroxide, etc.). In addition, a phosphate buffer, a histidine buffer, and a trimethylamine salt (e.g., Tris) can be used.
[0019] Preservatives may be added to retard microbial growth and may be added in an amount ranging from 0.2% to 1% (w / v). Preservatives suitable for use in the present disclosure include phenol, benzyl alcohol, m-cresol, methylparaben, propylparaben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides (e.g., chlorides, bromides, and iodides), hexamethonium chloride, and alkylparabens (e.g., methylparaben or propylparaben), catechol, resorcinol, cyclohexanol, and 3-pentanol.
[0020] Stabilizers (sometimes referred to as "isotonic agents") may be added to ensure the isotonicity of the liquid compositions of the present disclosure, and include polyols, such as triols or higher sugar alcohols, such as glycerol, erythritol, arabitol, xylitol, sorbitol, and mannitol. Stabilizers refer to a large class of excipients whose functions can range from fillers to additives that stabilize the therapeutic agent or help prevent denaturation or adhesion to the container wall. Typical stabilizers can be polyols (listed above); amino acids, such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, threonine, etc.; organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, dulcitol, glycerol, etc., including cyclitols, such as inositol; polyethylene glycol; Alcohol; amino acid polymer; sulfur-containing reducing agent such as urea, glutathione, lipoic acid, sodium thioglycolate, thioglycerol, α-thioglycerol and sodium thiosulfate; low molecular weight polypeptide (e.g., peptide of 10 residues or less); protein such as human serum albumin, bovine serum albumin, gelatin or immunoglobulin; hydrophilic polymer such as polyvinylpyrrolidone; monosaccharide such as xylose, mannose, fructose, glucose; disaccharide such as lactose, maltose, sucrose; trisaccharide such as raffinose; polysaccharide such as dextran. The stabilizer may be present in an amount of 0.1 to 10,000 parts by weight per part by weight of active protein.
[0021] Nonionic surfactants or detergents (also referred to as "wetting agents") can be added to help dissolve the therapeutic agent, and to protect the therapeutic protein from agitation-induced aggregation, which also allows the formulation to be exposed to stress shear surfaces without causing protein denaturation. Suitable nonionic surfactants include polysorbates (20, 80, etc.), polyoxamer (184, 188, etc.), polyols, polyoxyethylene sorbitan monoethers. Nonionic surfactants can exist in the range of about 0.05 mg / ml to about 1.0 mg / ml, for example, about 0.07 mg / ml to about 0.2 mg / ml.
[0022] The third aspect of the present invention provides a polynucleotide encoding the light chain variable region CDR of the monoclonal antibody according to the first aspect of the present invention.
[0023] Furthermore, the polynucleotide of the third aspect of the present invention comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 9, YTS, SEQ ID NO: 10 or a degenerate sequence thereof.
[0024] Furthermore, the polynucleotide of the third aspect of the present invention encodes the light chain variable region framework region of the monoclonal antibody of the first aspect of the present invention.
[0025] Furthermore, the polynucleotide of the third aspect of the present invention comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or a degenerate sequence thereof.
[0026] Furthermore, the polynucleotide of the third aspect of the present invention encodes the light chain variable region of the monoclonal antibody described above.
[0027] Furthermore, the polynucleotide of the third aspect of the present invention encodes a nucleotide sequence of the amino acid sequence shown in SEQ ID NO: 15 or a degenerate sequence thereof.
[0028] Furthermore, the homology between the degenerate sequence and the original sequence is greater than 60%.
[0029] Furthermore, the homology between the degenerate sequence and the original sequence is greater than 90%.
[0030] Exemplarily, the homology of the degenerate sequence to the original sequence is 60% or more, for example, about 60% or more, about 70% or more, 71% or more, 72% or more, 73% or more, 74% or more, 75% or more, 76% or more, 77% or more, 78% or more, 79% or more, 80% or more, 81% or more, 82% or more, 83% or more, 84% or more, 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, 99.1% or more, 99.2% or more, 99.3% or more, 99.4% or more, 99.5% or more, 99.6% or more, 99.7% or more, 99.8% or more, or 99.9% or more, etc.
[0031] The fourth aspect of the present invention provides a polynucleotide encoding the heavy chain variable region CDR of the monoclonal antibody according to the first aspect of the present invention.
[0032] Furthermore, the polynucleotide of the fourth aspect of the present invention comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or a degenerate sequence thereof.
[0033] Furthermore, the polynucleotide of the fourth aspect of the present invention encodes the heavy chain variable region framework region of the monoclonal antibody of the first aspect of the present invention.
[0034] Furthermore, the polynucleotide of the fourth aspect of the present invention comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or a degenerate sequence thereof.
[0035] Furthermore, the polynucleotide of the fourth aspect of the present invention encodes the heavy chain variable region of the monoclonal antibody of the first aspect of the present invention.
[0036] Furthermore, the polynucleotide of the fourth aspect of the present invention encodes a nucleotide sequence of the amino acid sequence shown in SEQ ID NO: 8 or a degenerate sequence thereof.
[0037] Furthermore, the homology between the degenerate sequence and the original sequence is greater than 60%.
[0038] Furthermore, the homology between the degenerate sequence and the original sequence is greater than 90%.
[0039] The fifth aspect of the present invention provides a vector comprising the polynucleotide described in the third aspect of the present invention or the polynucleotide described in the fourth aspect of the present invention.
[0040] In some embodiments, expression vectors and expression control sequences are selected to be compatible with the expression host cell used.The antibody light chain gene and the antibody heavy chain gene can be inserted into separate vectors, or usually the two genes are inserted into the same expression vector.
[0041] In some embodiments, the antibody gene is inserted into an expression vector by standard methods (e.g., connection of complementary restriction sites on an antibody gene fragment and a vector, or connection of a flat end when no restriction sites are present). Before inserting the anti-E protein monoclonal antibody-related light chain or heavy chain sequence, the expression vector may already carry the antibody constant region sequence. For example, one approach to converting the anti-E protein monoclonal antibody-related VH and VL sequences into full-length antibody genes is to insert them into expression vectors that have encoded the heavy chain constant region and the light chain constant region, respectively, so that the VH segment is effectively connected to one or more CH segments in the vector, and the VL segment is effectively connected to the CL segment in the vector. In addition or alternatively, the recombinant expression vector may encode a signal peptide that facilitates secretion of the antibody chain from the host cell. The antibody chain gene may be cloned into a vector so that the signal peptide is connected to the amino acids of the antibody chain gene in frame. The signal peptide may be an immunoglobulin signal peptide or a heterologous signal peptide (i.e., a signal peptide from a non-immunoglobulin).
[0042] The sixth aspect of the present invention provides a host cell transformed with a polynucleotide, a polynucleotide pair or a vector suitable for expressing the monoclonal antibody according to the first aspect of the present invention.
[0043] In some embodiments, to recombinantly express antibodies, host cells are transfected with one or more recombinant expression vectors carrying DNA fragments of immunoglobulin light and heavy chains encoding antibodies, so that the light and heavy chains are expressed in the host cells and optionally secreted into the culture medium in which the host cells are cultured, and the antibodies can be recovered from the culture medium. Standard recombinant DNA methods are used to obtain antibody heavy and light chain genes, incorporate these genes into recombinant expression vectors, and introduce the vectors into host cells, such as Molecular Cloning; A Laboratory Manual, Second Edition (Sambrook, Fritsch and Maniatis, Cold Spring Harbor, NY, 1989); Current Protocols in Molecular Biology (Ausubel, FM et al., ed., Greene Publishing Associates, 1989); and those described in U.S. Pat. No. 4,816,397.
[0044] In some embodiments, the host cell capable of producing anti-E protein monoclonal antibodies is a hybridoma. Methods for producing hybridomas are known in the art (see, e.g., Kohler and Milstein, 1975, Nature 256: 495), and examples are provided below. Typically, a host animal (such as a mouse) is immunized with an immunogen (such as a peptide of interest) to elicit the development of lymphocytes (such as spleen cells) that produce antibodies that can specifically bind to the immunogen. Alternatively, isolated lymphocytes (including spleen cells, lymph node cells, or peripheral blood lymphocytes) can be immunized in vitro. The lymphocytes are then fused with an immortalized cell line (such as a myeloma cell line) using a suitable fusion agent (e.g., polyethylene glycol) to form a hybridoma cell line. Suitable immortalized cell lines can be of mammalian origin, such as mice, cattle, or humans. The hybridoma cells are then cultured in any suitable culture medium containing one or more substances that inhibit the growth or survival of unfused immortalized cells. For example, when parental cells lacking hypoxanthine guanine phosphoribosyltransferase (HGPRT or HPRT) are used, the fusion can be cultured in a medium containing hypoxanthine, aminopterin, and thymidine ("HAT" medium) that inhibits the growth of the parental unfused cells.
[0045] The seventh aspect of the present invention provides a method for preparing a monoclonal antibody fragment expressed by the monoclonal antibody described in the first aspect of the present invention, the polynucleotide described in the third aspect of the present invention, or the polynucleotide described in the fourth aspect of the present invention, comprising: expressing the polynucleotide described in the third aspect of the present invention or the polynucleotide described in the fourth aspect of the present invention in a host cell.
[0046] The eighth aspect of the present invention provides a kit for detecting papillomavirus type 18 E protein or papillomavirus, comprising the monoclonal antibody described in the first aspect of the present invention.
[0047] Furthermore, the monoclonal antibody is linked to a detectable label, and the detectable label does not affect the function of the monoclonal antibody itself.
[0048] Furthermore, the monoclonal antibodies described above can be used in the detection of papillomavirus, for example, to detect the expression of the target of interest in specific cells, tissues or serum.
[0049] Further, the kits can be used as part of a clinical testing method to monitor the development or progression of an immune response, for example to determine the efficacy of a given treatment regimen.
[0050] In some embodiments, detection can be facilitated by coupling the antibody to a detectable substance or "label". The label can be directly or indirectly conjugated to the anti-E protein monoclonal antibody of the present disclosure. The label can be detectable by itself (e.g., radioisotope labeling, isotope labeling, or fluorescent labeling), or in the case of enzyme labeling, it can catalyze a detectable chemical change in a substrate compound or composition. Examples of detectable substances include a variety of enzymes, prosthetic groups, fluorescent substances, luminescent substances, bioluminescent substances, radioactive substances, positron-emitting metals using a variety of positron imaging techniques, and non-radioactive paramagnetic metal ions. The detectable substance can be coupled or conjugated to the antibody (or its fragment) directly or indirectly through an intermediate (e.g., a linker known in the art) using techniques known in the art. Examples of enzyme labels include luciferases (e.g., firefly luciferase and bacterial luciferase; U.S. Pat. No. 4,737,456), luciferin, 2,3-dihydrophthalazinedione, malate dehydrogenase, urease, peroxidase (e.g., horseradish peroxidase (HRPO)), alkaline phosphatase, β-galactosidase, acetylcholinesterase, glucoamylase, lysozyme, sugar oxidases (e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase), heterocyclic oxidases (e.g., urate oxidase and xanthine oxidase), lactoperoxidase, microperoxidase, and the like. Examples of suitable prosthetic group complexes include streptavidin / biotin; examples of suitable fluorescent substances include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazine fluorescein, dansyl chloride, dimethylamine-1-naphthalenesulfonyl chloride or phycoerythrin, etc.; examples of luminescent substances include luminol; examples of bioluminescent substances include luciferase, luciferin and aequorin; examples of suitable isotopic substances include 13 C. 15 N and deuterium; examples of suitable radioactive materials include 125 I. 131 I. 111 In or 99 Tc.
[0051] Further, the papillomaviruses include HPV-1, HPV-5, HPV-8, HPV-14, HPV-20, HPV-21, HPV-25, HPV-47, HPV-6, HPV-11, HPV-16, HPV-18, HP V-31, HPV-33, HPV-35, HPV-39, HPV-41, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-70, HPV-72.
[0052] Furthermore, the papillomavirus includes HPV-18.
[0053] The ninth aspect of the present invention provides the use of the monoclonal antibody described in the first aspect of the present invention, the polynucleotide described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, the vector described in the fifth aspect of the present invention, or the host cell described in the sixth aspect of the present invention in the preparation of a product for detecting papillomavirus, papillomavirus type 18 E protein or its fragments.
[0054] Further, the papillomaviruses include HPV-1, HPV-5, HPV-8, HPV-14, HPV-20, HPV-21, HPV-25, HPV-47, HPV-6, HPV-11, HPV-16, HPV-18, HP V-31, HPV-33, HPV-35, HPV-39, HPV-41, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-70, HPV-72.
[0055] Furthermore, the papillomavirus includes HPV-18.
[0056] The tenth aspect of the present invention provides a method for detecting HPV (papillomavirus), comprising the step of contacting a sample to be detected with the monoclonal antibody provided by the first aspect of the present invention.
[0057] The eleventh aspect of the present invention provides a method for treating and preventing HPV (papillomavirus), comprising administering to a subject an effective amount of the monoclonal antibody provided by the first aspect of the present invention for treating the HPV.
[0058] The treatment method generally includes administering an anti-E protein monoclonal antibody and / or a pharmaceutical composition thereof in an amount effective to provide a therapeutic benefit to a subject in need of treatment (e.g., a subject diagnosed with HPV). The therapeutic benefits described in more detail below include any improvement in HPV disease, such as slowing or stopping the progression of HPV, reducing the severity of HPV onset, inhibiting the growth or proliferation of HPV virus, and reducing the serum level of HPV virus in HPV patients. The subject can be human or non-human, including domestic animals (e.g., cats, dogs, cattle, pigs, horses) or non-domestic animals. Preferably, the anti-E protein monoclonal antibody is specific to the HPV of the species being treated. For example, anti-human E protein antibodies are administered to human patients, anti-dog E protein antibodies are administered to canine patients, and the like. Subjects treated with anti-human E protein monoclonal antibody therapy can be patients at any stage of disease progression.
[0059] The twelfth aspect of the present invention provides a method for inhibiting HPV virus in cells or tissues in vitro, which comprises exposing cells or tissues containing HPV virus to the monoclonal antibody provided by the first aspect of the present invention.
[0060] The term "monoclonal antibody" used in the present invention can be a full-length antibody, a multi-chain or single-chain antibody, a fragment of such an antibody that selectively binds to the E protein (including but not limited to Fab, Fab', (Fab')2, Fv and scFv), a surrobody (including a surrogate light chain construct), a single domain antibody, a humanized antibody, a camelized antibody, and the like. They can also belong to or be derived from any isotype, including, for example, IgA (e.g., IgA1 or IgA2), IgD, IgE, IgG (e.g., IgG1, IgG2, IgG3 or IgG4), or IgM. In some embodiments, the anti-E protein antibody is an IgG (e.g., IgG1, IgG2, IgG3 or IgG4).
[0061] The term "monoclonal antibody" as used herein is not limited to antibodies produced by hybridoma technology. Monoclonal antibodies are derived from a single clone (including any eukaryotic, prokaryotic or phage clone) by any means available or known in the art. Monoclonal antibodies for use in the present disclosure can be prepared using a variety of techniques known in the art (including the use of hybridoma technology, recombinant technology, and phage display technology or a combination thereof). In many uses of the present disclosure (including in vivo use of anti-E protein monoclonal antibodies in humans and in vitro detection assays), chimeric antibodies, primatized antibodies, humanized antibodies, or human antibodies can be suitably used.
[0062] The CDR used in the present invention is also referred to as the hypervariable region in both the light chain and the heavy chain variable domain. CDR is the complementary determining region of a monoclonal antibody. In addition, the more highly conserved part of the variable domain in a monoclonal antibody is called a framework region (FR). As known in the art, depending on the background and various definitions known in the art, the amino acid position / boundary describing the hypervariable region of an antibody may be different. Some positions in the variable domain may be considered as hybrid hypervariable positions, because these positions may be considered to be within the hypervariable region under a set of criteria, and these positions may be considered to be outside the hypervariable region under a different set of criteria. One or more of these positions may also be found in an extended hypervariable region. The present disclosure provides antibodies comprising modifications in these hybrid hypervariable positions. The variable domains of the natural heavy and light chains each include four FR regions, which are mainly in a β-folded conformation, connected by three CDRs, which form a loop connection, and in some cases form part of a β-folded structure. The CDRs in each chain are kept together in close proximity by the FR region, and together with the CDRs from other chains, contribute to the formation of an antibody target binding site.
[0063] The present invention also includes monoclonal antibodies for diagnostic and therapeutic applications that are derivatized, covalently modified, or conjugated to other molecules, for example, but not limited to, derivative antibodies include antibodies that have been modified, for example, by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protection / blocking groups, protease cleavage, connection to cellular ligands or other proteins, etc. Any of a number of chemical modifications can be performed by known techniques (including but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc.). In addition, the derivatives may contain one or more non-classical amino acids. BRIEF DESCRIPTION OF THE DRAWINGS
[0064] Figure 1 It is the electrophoresis diagram of monoclonal antibody 4F2;
[0065] Figure 2 It is the HPLC chart of monoclonal antibody 4F2;
[0066] Figure 3 It is the active binding diagram of monoclonal antibody 4F2. DETAILED DESCRIPTION
[0067] The following embodiments are only used to understand the method and core idea of the present invention. It should be noted that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principles of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
[0068] Example 1
[0069] 1. Recombinant expression of immunogens
[0070] The human papillomavirus type 18 E protein sequence was synthesized and constructed into the pEM5.1 vector; the transfection plasmid was extracted; the HEK293 cells were transfected and the cells were cultured for 7 days; the supernatant was harvested, purified by Ni column, and the recombinant human papillomavirus type 18 E protein was obtained after concentration and replacement of buffer.
[0071] The recombinant human papillomavirus type 18 E protein sequence was obtained from Uniprot.
[0072] The sequence information is as follows:
[0073] (SEQ ID NO:16)
[0074] 2. Immunity
[0075] Immunization of mice, SP2 / 0 fusion, screening, subcloning, the specific steps are:
[0076] The first immunization was performed with Freund's complete adjuvant, 100 μg per mouse, intraperitoneally, with a total dose of 0.5 ml / mouse. The second immunization was performed 3 weeks later. The second immunization was performed with Freund's incomplete adjuvant, with a dose of 50 μg / 0.5 ml / mouse. The third immunization was performed 2 weeks later. Cell fusion was prepared 10 days after the third injection.
[0077] Take feeder cells and press 10 5 / well, plate 10 one day before fusion 5 / 100μl / well; Mouse immune spleen cells were taken and fused with the prepared myeloma cells using the fusion agent PEG, and then plated into a 96-cell culture plate that had been added with feeder cells, 100μl / well.
[0078] Positive wells were screened by ELISA detection method, and recombinant human papillomavirus type 18 E protein was plated overnight; the plate was washed, and skimmed milk powder was added for blocking at 37°C for 1 hour; the plate was washed, and 100 μl of 96-well culture supernatant was added, and the plate was incubated at 37°C for 1 hour; the plate was washed, and HRP-labeled goat anti-mouse secondary antibody was added, and the plate was incubated at 37°C for 30 minutes; the plate was washed, and the color developing solution was added, and the color was developed for 10 minutes, and the stop solution was added to read the OD450 value; the high-expression cell lines were screened for subcloning.
[0079] 3. Sequence Retrieval
[0080] Collect cells, extract RNA, reverse transcribe, design primers, PCR, transform, select clones, send for sequencing, human papillomavirus type 18 E protein antibody, targeting E protein. Clone number 4F2, the specific sequence is shown in Table 1.
[0081] Table 1
[0082]
[0083]
[0084] 4. Antibody Expression
[0085] Monoclonal Antibody Expression and Purification:
[0086] (1) The screened sequences are chemically synthesized and cloned into a eukaryotic expression vector.
[0087] (2) Amplify and extract the plasmid.
[0088] (3) The antibody encoding plasmid was transiently transfected into mammalian HEK293 cells.
[0089] (4) Collect the supernatant and purify the monoclonal antibody using affinity chromatography.
[0090] HEK293 cells were used for transient transfection and PEI was used for transfection. The expression level of monoclonal antibody 4F2 was 187 mg / L.
[0091] 5. Physical and chemical properties
[0092] 5.1 Gel electrophoresis detection
[0093] A. Sample preparation
[0094] Take 20 μL of sample and mix it evenly with 5 μL of 5× reducing buffer, heat it at 95°C for 5 min, and cool it down; take 20 μL of sample and mix it evenly with 5 μL of 5× non-reducing buffer.
[0095] B. Electrophoresis
[0096] Prepare gel, add appropriate amount of electrophoresis buffer, add sample, and perform electrophoresis.
[0097] C. Dyeing and bleaching
[0098] After the electrophoresis is finished, take the gel and put it into an appropriate amount of Coomassie Brilliant Blue staining solution, and stain it at room temperature for 1 hour or longer; pour out the staining solution, add an appropriate amount of Coomassie Brilliant Blue staining decolorizing solution, and decolorize it at room temperature for 4-24 hours. After the decolorization is completed, soak it in ddH2O, refer to the marker protein, compare it with the unstained gel, cut out the gel of the required protein component, and collect it. Then separate the protein to be purified from the gel.
[0099] 5.2 HPLC detection of monoclonal antibody purity
[0100] A. Mobile phase preparation
[0101] Add potassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate and potassium chloride to about 900 mL of purified water, stir to dissolve, dilute to 1 L, measure with a pH meter to determine that the pH is between 6.2±0.1. Filter through a 0.22 μm filter membrane and store at room temperature.
[0102] B. Sample Preparation
[0103] System suitability sample: The standard was diluted to 2 mg / mL with mobile phase;
[0104] Test sample: Dilute the sample to be tested to 2 mg / mL with mobile phase.
[0105] The detection was carried out under conventional chromatographic conditions.
[0106] The results are as follows Figure 1 and Figure 2 As shown, the results showed that the purity of the monoclonal antibody 4F2 against papillomavirus type 18 E protein was greater than 95% by electrophoresis and liquid chromatography detection.
[0107] 6. Binding activity
[0108] Binding activity assay of monoclonal antibodies:
[0109] A. Coating: Dilute papillomavirus type 18 E protein to 2 μg / ml with coating solution, mix well, add to 96-well coating plate, 100 μl / well, seal with film, and incubate at 4°C overnight.
[0110] B. Wash the plate three times in a plate washer. No liquid should remain on the plate during the last wash. Pat the liquid on the surface of the plate dry with absorbent paper.
[0111] C. Blocking: Add 5% milk powder (0.5 g milk powder dissolved in 10 mL DPBS), 300 μL / well, incubate at 37°C for 1 h, and wash the plate 3 times according to step B.
[0112] D. Dilute the antibody in a gradient manner, 100 μL / well, react at 37°C for 1 h, and wash the plate 3 times according to step B.
[0113] E. Add secondary antibody: dilute with DPBS at 1:2000, add to 96-well plate, 100 μL / well, react at 37℃ for 1 hour, and wash the plate 3 times according to step B.
[0114] F. Color development: Add TMB, 100 μL / well, and develop color for 10 min at room temperature in the dark.
[0115] G. Stop: Add 2N H2SO4, 100 μL / well.
[0116] H. Measure OD450 with an enzyme-labeled instrument within 10 minutes.
[0117] Coat VP1 protein, add antibody, add secondary antibody, develop color, read, and analyze data.
[0118] The results are as follows Figure 3 As shown, the results showed that the EC50 of the papillomavirus type 18 E protein monoclonal antibody 4F2 was 1.5 ng / ml.
Claims
1. A monoclonal antibody that specifically binds to papillomavirus type 18 E protein, the monoclonal antibody comprising a heavy chain variable region, comprising a heavy chain CDR1 with an amino acid sequence as shown in SEQ ID NO: 1, a heavy chain CDR2 with an amino acid sequence as shown in SEQ ID NO: 2, and a heavy chain CDR3 with an amino acid sequence as shown in SEQ ID NO: 3; and a light chain variable region, comprising a light chain CDR1 with an amino acid sequence as shown in SEQ ID NO: 9, a light chain CDR2 with an amino acid sequence as shown in YTS, and a light chain CDR3 with an amino acid sequence as shown in SEQ ID NO:
10.
2. The monoclonal antibody according to claim 1, wherein the heavy chain variable region comprises a heavy chain variable region framework region, wherein the heavy chain variable region framework region comprises a heavy chain FR1 of the amino acid sequence shown in SEQ ID NO:4 or a homologous sequence thereof, a heavy chain FR2 of the amino acid sequence shown in SEQ ID NO:5 or a homologous sequence thereof, a heavy chain FR3 of the amino acid sequence shown in SEQ ID NO:6 or a homologous sequence thereof, and a heavy chain FR4 of the amino acid sequence shown in SEQ ID NO:7 or a homologous sequence thereof; the light chain variable region comprises a light chain variable region framework region, wherein the light chain variable region framework region comprises a light chain FR1 of the amino acid sequence shown in SEQ ID NO:11 or a homologous sequence thereof, a light chain FR2 of the amino acid sequence shown in SEQ ID NO:12 or a homologous sequence thereof, a light chain FR3 of the amino acid sequence shown in SEQ ID NO:13 or a homologous sequence thereof, and a light chain FR4 of the amino acid sequence shown in SEQ ID NO:14 or a homologous sequence thereof; Preferably, the monoclonal antibody comprises a heavy chain variable region amino acid sequence of SEQ ID NO: 8 or a homologous sequence thereof and a light chain variable region amino acid sequence of SEQ ID NO: 15 or a homologous sequence thereof; Preferably, the homology between the homologous sequence and the original sequence is more than 60%; Preferably, the homology between the homologous sequence and the original sequence is more than 90%.
3. A composition comprising the monoclonal antibody according to claim 1 or 2 and a buffer, a stabilizer, a preservative, a nonionic detergent, and / or an antioxidant.
4. A polynucleotide encoding the light chain variable region CDR of the monoclonal antibody according to claim 1 or 2; Preferably, the polynucleotide comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 9, YTS, SEQ ID NO: 10 or a degenerate sequence thereof; Preferably, the polynucleotide encodes the light chain variable region framework region of the monoclonal antibody according to claim 1 or 2; Preferably, the polynucleotide comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or a degenerate sequence thereof; Preferably, the polynucleotide encodes the light chain variable region of the monoclonal antibody according to claim 1 or 2; Preferably, the polynucleotide encodes the nucleotide sequence of the amino acid sequence shown in SEQ ID NO: 15 or a degenerate sequence thereof; Preferably, the homology between the degenerate sequence and the original sequence is more than 60%; Preferably, the homology between the degenerate sequence and the original sequence is greater than 90%.
5. A polynucleotide encoding the heavy chain variable region CDR of the monoclonal antibody according to claim 1 or 2; Preferably, the polynucleotide comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or a degenerate sequence thereof; Preferably, the polynucleotide encodes the heavy chain variable region framework region of the monoclonal antibody according to claim 1 or 2; Preferably, the polynucleotide comprises a nucleotide sequence encoding the amino acid sequence shown in SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 or a degenerate sequence thereof; Preferably, the polynucleotide encodes the heavy chain variable region of the monoclonal antibody according to claim 1 or 2; Preferably, the polynucleotide encodes the nucleotide sequence of the amino acid sequence shown in SEQ ID NO: 8 or a degenerate sequence thereof; Preferably, the homology between the degenerate sequence and the original sequence is more than 60%; Preferably, the homology between the degenerate sequence and the original sequence is greater than 90%. A vector comprising the polynucleotide according to claim 4 or the polynucleotide according to claim 5.
7. A host cell transformed with a polynucleotide, a polynucleotide pair or a vector suitable for expressing the monoclonal antibody according to claim 1 or 2.
8. A method for preparing the monoclonal antibody according to claim 1 or 2, the polynucleotide according to claim 4 or the monoclonal antibody fragment expressed by the polynucleotide according to claim 5, comprising: Expressing the polynucleotide of claim 4 or the polynucleotide of claim 5 in a host cell.
9. A kit for detecting papillomavirus type 18 E protein or papillomavirus, comprising the monoclonal antibody of claim 1 or 2; Preferably, the monoclonal antibody is linked to a detectable label, and the detectable label does not affect the function of the monoclonal antibody itself; Preferably, the papillomaviruses include HPV-1, HPV-5, HPV-8, HPV-14, HPV-20, HPV-21, HPV-25, HPV-47, HPV-6, HPV-11, HPV-16, HPV-18, HP V-31, HPV-33, HPV-35, HPV-39, HPV-41, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-70, HPV-72; Preferably, the papillomavirus comprises HPV-18.
10. Use of the monoclonal antibody according to claim 1 or 2, the polynucleotide according to claim 4, the polynucleotide according to claim 5, the vector according to claim 6, or the host cell according to claim 7 in the preparation of a product for detecting papillomavirus, papillomavirus type 18 E protein or a fragment thereof; Preferably, the papillomaviruses include HPV-1, HPV-5, HPV-8, HPV-14, HPV-20, HPV-21, HPV-25, HPV-47, HPV-6, HPV-11, HPV-16, HPV-18, HP V-31, HPV-33, HPV-35, HPV-39, HPV-41, HPV-45, HPV-51, HPV-52, HPV-56, HPV-58, HPV-59, HPV-68, HPV-70, HPV-72; Preferably, the papillomavirus comprises HPV-18.
Citation Information
Patent Citations
Reducing interference in ligand-receptor binding assays
US4737456A
Multichain polypeptides or proteins and processes for their production
US4816397A
Anti-human papilloma virus L1 protein antibody, and coding gene and application thereof
CN103694345A
Monoclonal antibody for resisting helicobacter pylori UreA protein and application thereof
CN117050168A
Immunological test for the detection of E7 oncoproteins in biological samples
EP3015863A1
Cited By
Specific antibodies against HPV-18 type E protein and uses thereof
CN119060173A
Specific antibodies against HPV-18 type E protein and uses thereof
CN119060173B
